UNICANCER

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Phase 2Recruiting2026700 people22 Jun 2026clinicaltrials.gov

NCT07284394

Phase 3Not yet recruiting2026272 people16 Dec 2025clinicaltrials.gov

NCT06524583

Phase 2Recruiting2025198 people29 Jul 2024clinicaltrials.gov

NCT05615818

Phase 3Recruiting2024800 people14 Nov 2022clinicaltrials.gov

NCT04985266

CollaboratorPhase 2Recruiting20221,100 people2 Aug 2021clinicaltrials.gov

NCT04757337

Phase 3Status unknown2021214 people17 Feb 2021clinicaltrials.gov

NCT04747054

Phase 3Recruiting2021102 people10 Feb 2021clinicaltrials.gov

NCT04595565

CollaboratorPhase 3Active, not recruiting20201,332 people20 Oct 2020clinicaltrials.gov

NCT03838263

Phase 2Completed201962 people12 Feb 2019clinicaltrials.gov

NCT03774732

Phase 3Active, not recruiting2018327 people13 Dec 2018clinicaltrials.gov

NCT03609047

CollaboratorPhase 2Active, not recruiting2019366 people1 Aug 2018clinicaltrials.gov

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

CollaboratorPhase 3Active, not recruiting2017707 people21 Dec 2016clinicaltrials.gov

NCT02818725

Phase 3Completed2010133 people30 Jun 2016clinicaltrials.gov

NCT02375204

CollaboratorPhase 3Active, not recruiting2015420 people2 Mar 2015clinicaltrials.gov

NCT02363049

CollaboratorPhase 3Status unknown2014278 people13 Feb 2015clinicaltrials.gov

NCT02299999

Phase 2Active, not recruiting20141,460 people24 Nov 2014clinicaltrials.gov

NCT02215265

CollaboratorPhase 3Active, not recruiting20151,269 people13 Aug 2014clinicaltrials.gov

NCT01805271

Phase 3Active, not recruiting20131,278 people6 Mar 2013clinicaltrials.gov

NCT01357486

CollaboratorPhase 2Completed2011160 people20 May 2011clinicaltrials.gov

NCT00955240

Phase 2Terminated200916 people10 Aug 2009clinicaltrials.gov